Literature DB >> 18599355

Impact of myelin-specific antigen presenting B cells on T cell activation in multiple sclerosis.

Christopher T Harp1, Amy E Lovett-Racke, Michael K Racke, Elliot M Frohman, Nancy L Monson.   

Abstract

The role of B cells in the pathogenesis of Multiple Sclerosis (MS) is incompletely understood. Here we define a possible role for B cells as myelin-specific antigen presenting cells (B-APCs) in MS. Peripheral blood B cells (PBBC) isolated from both MS patients and healthy controls (HC) were activated in vitro with either CD40L/IL-4 or a Class B CpG oligodeoxynucleotide (CpG ODN)/IL-2. Both activation techniques induced PBBCs to upregulate CD80 and HLA-DR, rendering them more efficient APCs than resting B cells. Although the CD40L/IL-4 B-APCs were highly effective in eliciting CNS-antigen specific proliferation by autologous T cells, CpG ODN/IL-2 stimulated B cells were not. Furthermore, CD40L/IL-4 B-APC induced responses by autologous CD4(+) T cells were susceptible to blocking with anti-HLA-DR antibody, suggesting that T cell responses were specific for antigen presentation by B-APC. CNS-antigen specific CD8(+) T cell proliferation was also blocked by HLA-DR, suggesting that CD8(+) proliferation is in part dependent on CD4(+) help.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18599355     DOI: 10.1016/j.clim.2008.05.002

Source DB:  PubMed          Journal:  Clin Immunol        ISSN: 1521-6616            Impact factor:   3.969


  24 in total

1.  Role of B cells in presentation of autoantigens to CD4(+) T cells in patients with autoimmune thyroiditis.

Authors:  E M Kuklina; E N Smirnova; I V Nekrasova; T S Balashova
Journal:  Dokl Biol Sci       Date:  2015-11-04

2.  Targeting B cells in the treatment of multiple sclerosis: recent advances and remaining challenges.

Authors:  Klaus Lehmann-Horn; Helena C Kronsbein; Martin S Weber
Journal:  Ther Adv Neurol Disord       Date:  2013-05       Impact factor: 6.570

3.  Memory B cells from a subset of treatment-naïve relapsing-remitting multiple sclerosis patients elicit CD4(+) T-cell proliferation and IFN-γ production in response to myelin basic protein and myelin oligodendrocyte glycoprotein.

Authors:  Christopher T Harp; Sara Ireland; Laurie S Davis; Gina Remington; Bonnie Cassidy; Petra D Cravens; Olaf Stuve; Amy E Lovett-Racke; Todd N Eagar; Benjamin M Greenberg; Michael K Racke; Lindsay G Cowell; Nitin J Karandikar; Elliot M Frohman; Nancy L Monson
Journal:  Eur J Immunol       Date:  2010-10       Impact factor: 5.532

4.  Estrogen-induced protection against experimental autoimmune encephalomyelitis is abrogated in the absence of B cells.

Authors:  Sheetal Bodhankar; Chunhe Wang; Arthur A Vandenbark; Halina Offner
Journal:  Eur J Immunol       Date:  2011-03-17       Impact factor: 5.532

5.  In vivo sensitized and in vitro activated B cells mediate tumor regression in cancer adoptive immunotherapy.

Authors:  Qiao Li; Seagal Teitz-Tennenbaum; Elizabeth J Donald; Mu Li; Alfred E Chang
Journal:  J Immunol       Date:  2009-08-10       Impact factor: 5.422

6.  Changes in B- and T-lymphocyte and chemokine levels with rituximab treatment in multiple sclerosis.

Authors:  Laura Piccio; Robert T Naismith; Kathryn Trinkaus; Robyn S Klein; Becky J Parks; Jeri A Lyons; Anne H Cross
Journal:  Arch Neurol       Date:  2010-06

Review 7.  The role of B cells in the immunopathogenesis of multiple sclerosis.

Authors:  Tohid Gharibi; Zohreh Babaloo; Arezoo Hosseini; Faroogh Marofi; Abbas Ebrahimi-Kalan; Saeed Jahandideh; Behzad Baradaran
Journal:  Immunology       Date:  2020-05-10       Impact factor: 7.397

Review 8.  Role of platelets in neuroinflammation: a wide-angle perspective.

Authors:  Lawrence L Horstman; Wenche Jy; Yeon S Ahn; Robert Zivadinov; Amir H Maghzi; Masoud Etemadifar; J Steven Alexander; Alireza Minagar
Journal:  J Neuroinflammation       Date:  2010-02-03       Impact factor: 8.322

9.  Impaired T cell activation and cytokine production by calcitriol-primed human B cells.

Authors:  G Drozdenko; T Scheel; G Heine; R Baumgrass; M Worm
Journal:  Clin Exp Immunol       Date:  2014-11       Impact factor: 4.330

10.  Insights into the Mechanisms of the Therapeutic Efficacy of Alemtuzumab in Multiple Sclerosis.

Authors:  Mark S Freedman; Johanne M Kaplan; Silva Markovic-Plese
Journal:  J Clin Cell Immunol       Date:  2013-07-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.